Continued evaluation of long-term safety, optimal treatment timing, and broader application across glioma grades is needed, but vorasidenib signifies a transformative step in the multidisciplinary management of IDH-mutant gliomas. This evidence concerns the gene IDH2 and central nervous system cancer.